CRADLE 1 Trial
CRADLE 1 incorporated field studies in Tanzania, Zambia and Zimbabwe, funded by a $100,000 Bill and Melinda Gates Foundation (BMGF) grant. Pregnant women were more commonly referred from community to health facility following the introduction of the device to local clinics than previously. It was also well accepted by users.
CRADLE 2 Trial (2015 – 2016)
Following the success of CRADLE 1 the Kings CRADLE group were successful in obtaining generous further funding from the Bill & Melinda Gates Grand Challenges Explorations ($1 Million). During this second phase of the project which took place in Mozambique, South Africa, Nigeria, India and Pakistan, the device was developed for improved accuracy in detection of low blood pressure and shock, and the traffic light early-warning-system was included.
CRADLE 3 Trial (2016-2018)
The primary aim was to determine whether widespread introduction of the Cradle VSA could reduce maternal mortality and major morbidity in 10 low-resource settings (Cap Hatien, Haiti; Freetown, Sierra Leone; Ndola, Zambia; Lusaka, Zambia; Harare, Zimbabwe; Gokak, India; Addis Ababa, Ethiopia; Mbale, Uganda; Zomba, Malawi). Maternal mortality and morbidity was reduced by up to 60% and 40% respectively in some sites.
VeSPA Trial (2018)
Vital Signs Alert Evaluating Shock Index in Pregnancy Anaemia
Up to 90% of pregnant women are anaemic in parts of rural India leading to increased risk of stillbirth, neonatal death and low birth weight. We carried out a study in 638 pregnant women attending antenatal care in Karnataka State in Southwest India, and found that the CRADLE VSA can be used to detect women who are likely to be suffering from anaemia, indicating that it can be used as a simple, cheap screening tool to highlight women needing iron supplementation.